Abhishek Sinha
The ₹28 crore IPO of Invicta Diagnostics opened for subscription on Monday, December 1, and will remain open until Wednesday, December 3. The diagnostic services provider aims to deploy the majority of the funds toward setting up new centres in Maharashtra.
Subscription Status — Day 1
The public offer witnessed a muted response on the first day, with the IPO being subscribed 9% by 2 pm.
-
Total bids received: 2,19,200 shares
-
Total shares on offer: 23,44,000 shares
Break-up of Day 1 subscription:
| Investor Category | Subscription |
|---|---|
| Retail Investors | 13% |
| Non-Institutional Investors (NIIs) | 11% |
| Qualified Institutional Buyers (QIBs) | No bids yet |
GMP (Grey Market Premium)
The GMP (grey market premium) stood at ₹0, indicating that Invicta Diagnostics shares were trading at par with the upper end of the price band in the grey market.
At current sentiment, the expected listing price is around ₹85.
Key IPO Details
| Particulars | Details |
|---|---|
| IPO Size | ₹28.12 crore |
| Price Band | ₹80 – ₹85 per share |
| Issue Type | Fresh issue of 0.33 crore equity shares |
| Anchor Investment | ₹6.79 crore raised on November 28 |
| Listing Platform | NSE SME |
| Basis of Allotment | Expected on December 4 |
| Listing Date | December 8 |
Utilisation of Proceeds
Invicta Diagnostics plans to allocate:
-
₹21.11 crore for the purchase of medical equipment and installation of five new diagnostic centres in Maharashtra
-
Remaining funds for general corporate purposes
Business Overview
Invicta Diagnostics operates under the brand “PC Diagnostics” and offers a wide range of radiology and pathology services, including imaging and teleradiology. The company currently runs seven diagnostic centres and one central laboratory in Mumbai.
Other Details
-
Socradamus Capital — Book-running lead manager
-
Bigshare Services — Registrar to the issue
-
Lot size — 1,600 shares
-
Minimum retail investment — Two lots, amounting to ₹2,72,000 at the upper price band
📌 Disclaimer: This article is for informational purposes only and should not be viewed as investment advice. Market investments are subject to risk; readers should evaluate their financial goals and consult professionals before investing.
